Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

HIV-associated lipodystrophy often includes excess accumulation of visceral fat.

Recombinant human growth hormone (rhGH) is a potential treatment for the excess visceral fat.

Who Took Part

According to the abstract, 26 men were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Thirty HIV-positive participants (26 men and 4 women) with visceral adiposity were enrolled.

How the Study Was Run

The design is described as open-label.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

The main outcome measure was change in visceral adipose tissue (VAT) on whole-body magnetic resonance imaging scan.

Changes in whole-body subcutaneous adipose tissue and skeletal muscle, glucose metabolism, serum lipids, and quality of life were also assessed.

PubMed files the paper under topics including Adipose Tissue, Blood Glucose, Body Composition, Growth Hormone, HIV Infections, Human Growth Hormone and Insulin.

What This Means in Plain Language

The paper is an open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 26 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (Journal of acquired immune deficiency syndromes (1999)), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.